The question of whether NMN is safe during pregnancy or breastfeeding has a straightforward answer from an evidence standpoint: no adequate human safety data exists for either situation, and the available animal data raises questions that make precautionary avoidance the appropriate recommendation. This is not an unusually restrictive position — the same recommendation applies to the vast majority of supplements, including many that are entirely benign in non-pregnant adults, simply because pregnancy safety testing is expensive, ethically constrained, and therefore rarely conducted for supplement ingredients.
What makes NMN worth discussing specifically in this context is that NAD+ is not a peripheral nutrient — it is a central metabolic regulator involved in embryonic and fetal development in ways that make the question of supplemental NAD+ elevation during pregnancy more substantive than the standard supplement-in-pregnancy caution.
If you are pregnant, planning pregnancy, or breastfeeding and considering NMN or NR supplementation, please discuss this with your obstetrician or midwife before starting. The information in this article is not a substitute for personalized medical guidance.
Contents
Why NAD+ Matters During Development
NAD+ is not merely an energy carrier during fetal development — it plays specific and essential roles in the developmental processes that create a healthy fetus. Understanding these roles explains why the question of supplemental NAD+ during pregnancy is more nuanced than simply asking whether a compound is toxic.
NAD+ is required for the activity of sirtuins including SIRT1, which regulates epigenetic programming during embryogenesis. The epigenetic landscape of the developing embryo — which genes are silenced, which are active, and how this changes across developmental stages — is exquisitely sensitive to the metabolic and enzymatic environment. SIRT1-mediated histone deacetylation contributes to the establishment of tissue-specific gene expression patterns that define cellular identity during development. Disrupting this process — in either direction — carries theoretical risks.
NAD+ is also required for PARP enzymes that participate in DNA repair during the rapid cell division of embryonic development. Some PARP family members play direct roles in cellular differentiation independent of their DNA repair function. The precise balance of PARP activity during development is important: insufficient NAD+ impairs repair, while excessive PARP activation can alter the differentiation signals that depend on NAD+ availability.
Research has demonstrated that NAD+ deficiency during pregnancy produces severe developmental abnormalities in animal models. Shi et al. (2017) in Nature Medicine found that NAD+ deficiency during mouse and human pregnancy is associated with multiple congenital abnormalities — a finding that established adequate NAD+ as essential for normal development. This research was widely cited as evidence that NAD+ matters for fetal health. What it does not establish is that supplemental NMN above normal dietary intake improves outcomes or is safe — the study identified a deficiency problem, not a case for supplementation above normal levels.
Animal Data: What It Shows and Its Limits
The animal data on NAD+ precursor supplementation during pregnancy is limited and not uniformly reassuring. Several concerns have emerged:
Studies in mice examining high-dose NMN during pregnancy have raised concerns about potential effects on placental function and fetal development at doses substantially above typical supplemental amounts. The relevance of high-dose animal findings to human supplemental doses is uncertain — the doses used in animal studies are often much higher than human supplemental doses when scaled for body weight, and mouse metabolism differs significantly from human metabolism. That said, the findings are sufficient to warrant caution rather than dismissal.
A separate concern involves the potential for NAD+ precursor supplementation to alter the methylation demands during fetal development. As covered in the article on NMN + TMG stacking, NAD+ metabolism consumes methyl groups, and adequate methylation is critically important during fetal development — folate and B12 are essential pregnancy nutrients specifically because of their methyl-donating roles in DNA methylation and neural tube closure. The interaction between NMN supplementation’s methyl demand and the existing methyl requirements of pregnancy has not been studied in humans.
The Breastfeeding Question
NMN and its metabolites are present in breast milk naturally — NR has been identified in human milk, suggesting that NAD+ precursors do cross into milk. Whether supplementing at longevity doses meaningfully elevates breast milk NMN or NR concentrations, and whether elevated concentrations affect the nursing infant, has not been studied. The infant’s NAD+ system is not the same as an adult’s — newborns and young infants are still developing their NAD+ biosynthesis and regulation systems, and the appropriate NAD+ environment for an infant is not simply “more is better” scaled from adult longevity reasoning.
The absence of safety data for breastfeeding mothers, combined with the theoretical concerns about elevated NAD+ precursor exposure in developing infants, supports the recommendation to avoid NMN and NR supplementation while breastfeeding unless a healthcare provider has specifically reviewed and approved it for your circumstances.
What About Niacin and Folate During Pregnancy?
Prenatal vitamins routinely contain niacin (vitamin B3) — typically at 18–20 mg, the recommended dietary allowance for pregnant women. This is a NAD+ precursor that is not only considered safe but is recommended during pregnancy. The distinction between prenatal vitamin niacin and NMN supplementation at longevity doses is primarily one of dose: prenatal niacin at RDA levels maintains normal NAD+ biosynthesis; NMN at 500–1,000 mg/day elevates NAD+ substantially above baseline. It is the supraphysiological elevation, not the nutrient itself, that raises questions in the pregnancy context.
Folate (or its active form methylfolate) is the prenatal supplement most directly connected to methylation and developmental outcomes — its role in preventing neural tube defects is one of the most established supplement safety findings in all of medicine. Adequate folate intake during pregnancy is non-negotiable and is entirely distinct from the NMN question.
Practical Guidance
For women who are pregnant, trying to conceive, or breastfeeding, the practical guidance is clear:
Discontinue NMN and NR supplementation before attempting conception or as soon as pregnancy is confirmed, and do not resume until breastfeeding is complete and you have discussed NAD+ supplementation with your healthcare provider. This is a conservative recommendation, and it may prove to be more cautious than necessary if future research shows NMN to be safe in pregnancy — but it is the appropriate position given the current absence of human safety data and the developmental significance of NAD+ metabolism.
Continue taking a quality prenatal vitamin with methylfolate (not folic acid, particularly for women with MTHFR variants), adequate vitamin D, DHA, and iron as recommended by your obstetrician. These are nutrients with established safety profiles and evidence-based benefits during pregnancy and breastfeeding. The longevity supplement protocol can resume after breastfeeding is complete.
If you have specific concerns about NAD+ status during pregnancy — for example, if you have been diagnosed with a condition associated with NAD+ deficiency or have nutritional concerns — discuss this with your obstetrician or a maternal-fetal medicine specialist rather than self-supplementing with NMN.
Resuming After Breastfeeding
Once breastfeeding is complete, there is no established reason related to prior pregnancy or breastfeeding that would require a waiting period before resuming NMN or NR supplementation. The post-partum period can be physiologically demanding — sleep deprivation, hormonal changes, and the nutritional demands of milk production all represent stressors that deplete NAD+. Some women find the post-breastfeeding transition a natural point at which to reassess and resume a longevity supplement protocol. Restarting at a standard dose with attention to adequate TMG, vitamin D, and other foundational stack components is the appropriate approach.
Frequently Asked Questions
I accidentally took NMN before knowing I was pregnant. Should I be worried?
A brief period of NMN use before pregnancy was confirmed is very unlikely to cause harm based on the limited available data. The concerns about NMN during pregnancy are primarily theoretical or derived from high-dose animal studies, not from evidence of human developmental harm at typical supplemental doses. Discontinue NMN now that you are aware of the pregnancy, and discuss the situation with your obstetrician for reassurance and guidance. There is no established basis for alarm from brief unintentional NMN use in early pregnancy, but your obstetrician is the appropriate source of personalized guidance.
What about NR specifically — is it safer than NMN during pregnancy?
The same considerations apply to NR as to NMN. Both are NAD+ precursors that elevate NAD+ above baseline through the same pathway, and the concerns about supraphysiological NAD+ elevation during fetal development apply to both. NR appears naturally in breast milk, which might suggest it is safer than NMN in the breastfeeding context — but the presence of trace NR in breast milk does not establish that supplemental doses are safe. The recommendation is the same for both: avoid during pregnancy and breastfeeding without specific medical guidance.
Can I take resveratrol during pregnancy?
No. Resveratrol is specifically contraindicated during pregnancy based on animal data showing it can cross the placenta and affect fetal development. Several animal studies have found that resveratrol at doses relevant to supplementation produces adverse pregnancy and fetal outcomes including intrauterine growth restriction. Resveratrol should be discontinued before conception and not resumed until after breastfeeding. This is a more established contraindication than NMN’s, based on more direct animal safety data.
Are there any longevity-relevant supplements that are safe during pregnancy?
Prenatal vitamins with methylfolate and DHA are the clearest evidence-supported supplements for pregnancy, with established safety and documented developmental benefits. Vitamin D at recommended doses is appropriate with monitoring of serum levels. Magnesium glycinate is generally well-tolerated and useful for pregnancy-related muscle cramps and sleep. Beyond standard prenatal supplementation, the compounds discussed in longevity contexts — NMN, NR, resveratrol, quercetin, fisetin, berberine — are all either contraindicated or insufficiently studied for use during pregnancy. The longevity protocol is best deferred until after breastfeeding is complete.